99% Lincocin Pharmaceutical Raw Materials CAS 859-18-7 Lincomycin Hydrochloride (Email: linda@hubeijusheng.com) CAS NO.859-18-7

 
Product Name: Lincomycin Hydrochloride
Synonyms: Lincomycin Hcl; lincomycin hydrochloride; methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside hydrochloride; Lincomycin hydrochloride anhydrous; methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside hydrochloride (1:1); hydrogen chloride methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-gluco-octopyranoside (1:1:1);;
CAS No.: 859-18-7
EINECS No.: 212-726-7
Molecular formula: C18H35ClN2O6S
Molecular weight: 442.99
Appearance: white crystalline powder
 
99% Lincocin Pharmaceutical Raw Materials Lincomycin Hydrochloride CAS 859-18-7
 
 
Quick Details:
 
·                  Lincomycin hydrochloride
·                  Alias: Lincomycin HCL, Lincomycin, Lincocin
·                  CAS Registry Number: 859-18-7
·                  Assay: 99%
·                  Formula: C18H34N2O6S.HCl
·                  Molecular Weight:443.06
·                  EINECS: 212-726-7
·                  Appearance: white powder
·                  Related Substances: Pharmaceutical Grade
·                  Storage: Shading, confined preservation
·                  Manufacturer: Hezhong
Usage: Anesthetic Agents, Anti-Allergic Agents

Applications:
 
Lincomycin is a lincosamide antibiotic that comes from the actinomyces Streptomyces lincolnensis.A related compound, clindamycin, is derived from lincomycin by using thionyl chloride to replace the 7-hydroxy group with a chlorine atom with inversion of chirality.
 
Although similar in structure, antibacterial spectrum, and mechanism of action to macrolides, lincomycin is also effective against other organisms including actinomycetes, mycoplasma, and some species of Plasmodium.Intramuscular administration of a single dose of 600 mg of Lincomycin produces average peak serum levels of 11.6 micrograms/ml at 60 minutes, and maintains therapeutic levels for 17 to 20 hours, for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 17.3 percent).
 
A two-hour intravenous infusion of 600 mg of Lincomycin achieves average peak serum levels of 15.9 micrograms/ml and yields therapeutic levels for 14 hours for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent).
 
The biological half-life after IM or IV administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function, compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum.
 
Tissue level studies indicate that bile is an important route of excretion. Significant levels have been demonstrated in the majority of body tissues. Although lincomycin appears to diffuse in the cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of meningitis.

Lincomycin Hydrochloride CAS 859-18-7 Lincomycin Hcl
Lincomycin Hydrochloride CAS 859-18-7 Lincomycin Hcl
Lincomycin Hydrochloride CAS 859-18-7 Lincomycin Hcl
Lincomycin Hydrochloride CAS 859-18-7 Lincomycin Hcl
Lincomycin Hydrochloride CAS 859-18-7 Lincomycin Hcl